Stratification of urinary bladder carcinoma based on immunohistochemical expression of CK5, CK14 and CK20

References

• Mitra, A. P. Molecular Substratification of Bladder Cancer: Moving Towards Individualized Patient Management. Ther. Adv. Urol. 2016, 8(3), 215–233.
   PubMed Web of Science ®Google Scholar
• Bilski, K.; Zapała, Ł.; Skrzypczyk, M. A.; Oszczudłowski, M.; Dobruch, J. Review on Gender Differences in Non-muscle Invasive Bladder Cancer. Transl. Androl. Urol. 1, 2019, 8(1), 12–20. DOI:10.21037/tau.2018.11.06.
   PubMed Web of Science ®Google Scholar
• Ibrahim, A. S.; Khaled, H. M.; Mikhail, N. N.; Baraka, H.; Kamel, H. Cancer Incidence in Egypt: Results of the National Population-based Cancer Registry Program. J. Cancer Epidemiol. 2014, 2014, 437971.
   PubMedGoogle Scholar
• Mokhtar, N.; Salama, A.; Badawy, O.; Khorshed, E.; Mohamed, G.; Ibrahim, M.; Abdelazim, H. Cancer Pathology Registry, A 12 Year Registery (2000–2011); Cairo university: Egypt, 2016.
   Google Scholar
• Antoni, S.; Ferlay, J.; Soerjomataram, I.; Znaor, A.; Jemal, A.; Bray, F. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur. Urol. 2016, 71(1), 96–108. DOI: 10.1016/j.eururo.2016.06.010.
   PubMed Web of Science ®Google Scholar
• Shin, K.; Lim, A.; Odegaard, J. I.; Honeycutt, J. D.; Kawano, S.; Hsieh, M. H.; Beachy, P. A. Cellular Origin of Bladder Neoplasia and Tissue Dynamics of Its Progression to Invasive Carcinoma. Nat. Cell Biol. 2014, 16(5), 469–478. DOI: 10.1038/ncb2956.
   PubMed Web of Science ®Google Scholar
• Volkmer, J. P.; Sahoo, D.; Chin, R. K.; Ho, P. L.; Tang, C.; Kurtova, A. V.; Willingham, S. B.; Pazhanisamy, S. K.; Contreras-Trujillo, H.; Storm, T. A.; et al. Three Differentiation States Risk-stratify Bladder Cancer into Distinct Subtypes. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(6), 2078–2083. DOI: 10.1073/pnas.1120605109.
   PubMed Web of Science ®Google Scholar
• Lerner, S. P.; McConkey, D. J.; Hoadley, K. A.; Chan, K. S.; Kim, W. Y.; Radvanyi, F.; Höglund, M.; Real, F. X. Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting. Bladder Cancer 2016, 2(1), 37–47. DOI: 10.3233/BLC-150037.
   PubMed Web of Science ®Google Scholar
• Rinaldetti, S.; Rempel, E.; Worst, T. S.; Eckstein, M.; Steidler, A.; Weiss, C. A.; Bolenz, C.; Hartmann, A.; Erben, P. Subclassification, Survival Prediction and Drug Target Analyses of Chemotherapy-naïve Muscle-invasive Bladder Cancer with a Molecular Screening. Oncotarget 2018, 9(40), 25935–25945. DOI: 10.18632/oncotarget.25407.
   PubMedGoogle Scholar
• McConkey, D. J.; Choi, W. Molecular Subtypes of Bladder Cancer. Curr. Oncol. Rep. 2018, 20(10), 77. DOI: 10.1007/s11912-018-0727-5.
   PubMed Web of Science ®Google Scholar
• Robertson, A. G.; Kim, J.; Al-Ahmadie, H.; Bellmunt, J.; Guo, G.; Cherniack, A. D.; Hinoue, T.; Laird, P. W.; Hoadley, K. A.; Akbani, R.; et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell 2018, 174, 1033. DOI: 10.1016/j.cell.2018.07.036.
   PubMed Web of Science ®Google Scholar
• Moch, H.; Humphrey, P. A.; Ulbright, T. M.; Reuter, V. WHO Classification of Tumours of the Urinary System and Male Genital Organs. International Agency for Research on Cancer, Lyon, France. 2016; pp 106–119.
   Google Scholar
• Gulmann, C.; Paner, G. P.; Parakh, R. S.; Hansel, D. E.; Shen, S. S.; Ro, J. Y.; Annaiah, C.; Lopez-Beltran, A.; Rao, P.; Arora, K.; et al. Immunohistochemical Profile to Distinguish Urothelial from Squamous Differentiation in Carcinomas of Urothelial Tract. Hum. Pathol. 2012, 44(2), 164–172. DOI: 10.1016/j.humpath.2012.05.018.
   PubMed Web of Science ®Google Scholar
• Samaratunga, H.; Fairweather, P.; Purdie, D. Significance of Stromal Reaction Patterns in Invasive Urothelial Carcinoma. Am. J. Clin. Pathol. 2005, 123(6), 851–857. DOI: 10.1309/EE8RTB6X1611G6TU.
   PubMed Web of Science ®Google Scholar
• Goyal, S.; Singh, U. R.; Sharma, S.; Kaur, N. Correlation of Mitotic Indices, AgNor Count, Ki-67 and Bcl-2 with Grade and Stage in Papillary Urothelial Bladder Cancer. Urology 2014, 11(1), 1238–1247.
   Web of Science ®Google Scholar
• Fedchenko, N.; Reifenrath, J. Different Approaches for Interpretation and Reporting of Immunohistochemistry Analysis Results in the Bone Tissue - A Review. Diagn. Pathol. 2014, 9(221). DOI: 10.1186/s13000-014-0221-9.
   PubMedGoogle Scholar
• Weyerer, V.; Weisser, R.; Moskalev, E. A.; Haller, F.; Stoehr, R.; Eckstein, M.; Zinnall, U.; Gaisa, N. T.; Compérat, E.; Perren, A.; et al. Distinct Genetic Alterations and Luminal Molecular Subtype in Nested Variant of Urothelial Carcinoma. Histopathology 2019, 75(6), 865–875.
   PubMed Web of Science ®Google Scholar
• Sikic, D.; Keck, B.; Wach, S.; Taubert, H.; Wullich, B.; Goebell, P. J.; Kahlmeyer, A.; Olbert, P.; Isfort, P.; Nimphius, W.; et al. Bridge Consortium. Immunohistochemiocal Subtyping Using CK20 and CK5 Can Identify Urothelial Carcinomas of the Upper Urinary Tract with a Poor Prognosis. PloS One 2017, 12(6), e0179602. DOI: 10.1371/journal.pone.0179602.
   PubMed Web of Science ®Google Scholar
• Zaghloul, M. S.; Gouda, I. Schistosomiasis and Bladder Cancer: Similarities and Differences from Urothelial Cancer. Expert Rev. Anticancer Ther. 2012, 12(6), 753–763. DOI: 10.1586/era.12.49.
   PubMed Web of Science ®Google Scholar
• Choi, W.; Ochoa, A.; McConkey, D. J.; Aine, M.; Höglund, M.; Kim, W. Y.; Real, F. X.; Kiltie, A. E.; Milsom, I.; Dyrskjøt, L.; et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. Eur. Urol. 2017, 72(3), 354–365. DOI: 10.1016/j.eururo.2017.03.010.
   PubMed Web of Science ®Google Scholar
• Hashmi, A. A.; Hussain, Z. F.; Irfan, M.; Edhi, M. M.; Kanwal, S.; Faridi, N.; Khan, A. Cytokeratin 5/6 Expression in Bladder Cancer: Association with Clinicopathologic Parameters and Prognosis. BMC Res. Notes. 2018, 11(1), 207. DOI: 10.1186/s13104-018-3319-4.
   PubMedGoogle Scholar
• Yuk, H. D.; Jeong, C. W.; Kwak, C.; Kim, H. H.; Moon, K. C.; Ku, J. H. Clinical Outcomes of Muscle Invasive Bladder Cancer according to the BASQ Classification. BMC Cancer. 2019, 19(1), 897. DOI: 10.1186/s12885-019-6042-1.
   PubMed Web of Science ®Google Scholar
• Makboul, R.; Hassan, H. M.; Refaiy, A.; Abdelkawi, I. F.; Shahat, A. A.; Hameed, D. A.; Morsy, A.; Salah, T.; Ahmed Mohammed, R. A. A Simple Immunohistochemical Panel Could Predict and Correlate to Clinicopathologic and Molecular Subgroups of Urinary Bladder Urothelial Carcinoma. Clin. Genitourin. Cancer 2019, 17(3), e712–e719. DOI: 10.1016/j.clgc.2019.04.011.
   PubMed Web of Science ®Google Scholar
• Gaisa, N. T.; Braunschweig, T.; Reimer, N.; Bornemann, J.; Eltze, E.; Siegert, S.; Toma, M.; Villa, L.; Hartmann, A.; Knuechel, R. Different Immunohistochemical and Ultrastructural Phenotypes of Squamous Differentiation in Bladder Cancer. Virchows Arch. Dec 7, 2010, 458(3), 301–312. DOI: 10.1007/s00428-010-1017-2.
   PubMed Web of Science ®Google Scholar
• Sui, X.; Lei, L.; Chen, L.; Xie, T.; Li, X. Inflammatory Microenvironment in the Initiation and Progression of Bladder Cancer. Oncotarget 2017, 8(54), 93279–93294. DOI: 10.18632/oncotarget.21565.
   PubMedGoogle Scholar
• Jiang, J.; Ulbright, T. M.; Younger, C.; Sanchez, K.; Bostwick, D. G.; Koch, M. O.; Eble, J. N.; Cheng, L. Cytokeratin 7 and Cytokeratin 20 in Primary Urinary Bladder Carcinoma and Matched Lymph Node Metastasis. Arch. Pathol. Lab. Med. 2001, 125, 921–923.
   PubMed Web of Science ®Google Scholar
• Hammam, O.; Wishahiz, M.; Khalil, H.; El Ganzouri, H.; Badawy, M.; Elkhquly, A.; Elesaily, K. Expression of Cytokeratin 7, 20, 14 in Urothelial Carcinoma and Squamous Cell Carcinoma of the Egyprian Urinary Bladder Cancer. J. Egypt. Soc. Parasitol. Dec 1, 2014, 44(3), 733–740. DOI: 10.12816/0007876.
   PubMedGoogle Scholar
• Moll, R.; Löwe, A.; Laufer, J.; Franke, W. W. Cytokeratin 20 in Human Carcinomas. A New Histodiagnostic Marker Detected by Monoclonal Antibodies. Am. J. Pathol. Feb 1, 1992, 140(2), 427–447.
   PubMed Web of Science ®Google Scholar
• Selves, J.; Long-Mira, E.; Mathieu, M. C.; Rochaix, P.; Ilié, M. Immunohistochemistry for Diagnosis of Metastatic Carcinomas of Unknown Primary Site. Cancers (Basel) 2018, 10(4). DOI: 10.3390/cancers10040108.
   PubMed Web of Science ®Google Scholar
• Ghaini, M. H.; Esmailnejad, S. S.; Davati, A. Cytokeratin 20 in Transitional Cell Carcinoma of Bladder and Its Relation with Prognostic Factors. Iran. J. Pathol. 2012, 7(3), 145–150.
   Google Scholar
• Pena, M. D. C. R.; Tregnago, A. C.; Chaux, A.; Paraguay, A.; Taheri, D.; Bohran, W.; Rezaei, K.; Eich, M.-L.; Nonogaki, H.; Sharma, R.; et al. Immunohistochemical Evaluation of Basal and Luminal Markers in Non-muscle Invasive Urothelial Carcinoma of Bladder (NMIBC). J. Urol. 2017, 197(4S, Supplement).
   Google Scholar
• Schaafsma, H. E.; Ramaekers, F. C.; van Muijen, G. N.; Lane, E. B.; Leigh, I. M.; Robben, H.; Huijsmans, A.; Ooms, E. C.; Ruiter, D. J. Distribution of Cytokeratin Polypeptides in Human Transitional Cell Carcinomas, with Special Emphasis on Changing Expression Patterns during Tumor Progression. Am. J. Pathol. 1990, 136(2), 329–343.
   PubMed Web of Science ®Google Scholar
• Moselhy, A. A.; Aiad, H. A.; Rebey, H. S.; Mahmoud, S. F. Immunohistochemical Expression of Cytokeratin 14 and Association with the Extent of Squamous Differentiation in Urothelial Carcinoma. Menoufia Med. J.. 2018, 31: 826–833.
   Google Scholar
• Rebola, J.; Aguiar, P.; Blanca, A.; Montironi, R.; Cimadamore, A.; Cheng, L.; Henriques, V.; Lobato-Faria, P.; Lopez-Beltran, A. Predicting Outcomes in Non-muscle Invasive (Ta/t1) Bladder Cancer: The Role of Molecular Grade Based on Luminal/basal Phenotype. Virchows Arch. 2019, 475(4), 445–455. DOI: 10.1007/s00428-019-02593-x.
   PubMed Web of Science ®Google Scholar
• Zheng, Y. L.; Amr, S.; Saleh, D. A.; Dash, C.; Ezzat, S.; Mikhail, N. N.; Gouda, I.; Loay, I.; Hifnawy, T.; Abdel-Hamid, M.; et al. Urinary Bladder Cancer Risk Factors in Egypt: A Multicenter Case-control Study. Cancer Epidemiol. Biomarkers Prev. 2012, 21(3), 537–546. DOI: 10.1158/1055-9965.EPI-11-0589.
   PubMed Web of Science ®Google Scholar
• Feng, H.; Zhang, W.; Li, J.; Lu, X. Different Patterns in the Prognostic Value of Age for Bladder Cancer-specific Survival Depending on Tumor Stages. Am. J. Cancer Res. 2015, 5(6), 2090–2097.
   PubMed Web of Science ®Google Scholar